Results: 5

1.
Fig. 1

Fig. 1. From: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

This was a non-randomised, open-label, Phase I safety and immunogenicity dose-finding study in healthy, previously BCG-vaccinated adults (Fig. 1). Participants were negative for HIV, HBV and HCV and aged 18–50 with no evidence of latent MTB infection, as determined by IFN-γ ELISPOT response to ESAT-6 and CFP-10.

Ansar A. Pathan, et al. Vaccine. 2012 August 17;30(38):5616-5624.
2.
Fig. 2

Fig. 2. From: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Severity of adverse events induced by immunisation with different doses of MVA85A. Severity of the most frequently reported local adverse events following immunisation with (A) 1 × 107 or (B) 1 × 108 PFU of MVA85A. Severity of the most frequently reported systemic adverse events following immunisation with (C) 1 × 107 or (D) 1 × 108 PFU of MVA85A. White: mild, grey: moderate and black: severe.

Ansar A. Pathan, et al. Vaccine. 2012 August 17;30(38):5616-5624.
3.
Fig. 5

Fig. 5. From: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Dose related differences in T cell response to MVA85A. The fold increase in the frequency of antigen specific T cells detected following immunisation with different doses of MVA85A at the peak of response (1 week) and long term (52 weeks) over the screening pre-immunisation responses were calculated for each dose. There was a significant difference in the fold increase between the high and low dose groups at 52 weeks, but no significant difference between high, mid or low doses at 1 week post immunisation.

Ansar A. Pathan, et al. Vaccine. 2012 August 17;30(38):5616-5624.
4.
Fig. 4

Fig. 4. From: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

T cell epitope display in adults vaccinated with either 1 × 107 or 1 × 108 PFU of MVA85A. A total of 66, 15-mer peptides overlapping by 10 amino acids (P1–P66) were used to map T cell responses to MVA85A. A) Open bars indicate individual peptide responses to 1 × 107 (n = 12) and black bars 1 × 108 PFU (n = 12) of MVA85A. B) The overall number of peptides detected in response to MVA85A is significantly higher in volunteers vaccinated with 1 × 108 (black circles) compared to 1 × 107 (white circles) PFU of MVA85A. Responses detected using an ex vivo IFN-γ ELISPOT assay, Mann–Whitney *p < 0.05.

Ansar A. Pathan, et al. Vaccine. 2012 August 17;30(38):5616-5624.
5.
Fig. 3

Fig. 3. From: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

T cell responses in adults vaccinated with either 1 × 107 or 1 × 108 PFU of MVA85A. Antigen specific T cells were detected in PBMC from healthy, previously BCG vaccinated adults receiving either 1 × 107 (panels A, C and E) or 1 × 108 (panels B, D and F) PFU of MVA85A. T cells were detected using an overnight ex vivo IFN-γ ELISPOT assay with summed peptide pool (A and B), Ag85A protein (C and D) or PPD (E and F). Wilcoxon matched-pairs signed rank when compared to baseline (screening visit): ***p < 0005, **p < 005, *p < 05.

Ansar A. Pathan, et al. Vaccine. 2012 August 17;30(38):5616-5624.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk